Active, not recruitingPHASE1, PHASE2NCT05520567
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Astellas Pharma Global Development, Inc.
- Principal Investigator
- Medical DirectorAstellas Pharma Global Development, Inc.
- Intervention
- Gilteritinib(drug)
- Enrollment
- 70 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (20)
- City of Hope Nat'l Medical Center, Duarte, California, United States
- Univ. of California - Irvine, Irvine, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Sarah Cannon Research Institute, Denver, Colorado, United States
- Memorial Cancer Institute, Pembroke Pines, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Maryland, Baltimore, Maryland, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Weill Cornell Medical College, New York, New York, United States
- Motefiore-Einstein Center for Cancer Care, The Bronx, New York, United States
- Novant Health, Winston-Salem, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05520567 on ClinicalTrials.govOther trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548710Study of SA+X in the Treatment of Newly Diagnosed AMLRuijin Hospital
- RECRUITINGNANCT07183878Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)First Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT04010877Multiple CAR-T Cell Therapy Targeting AMLShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE1, PHASE2NCT06129734Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantBenjamin Tomlinson
- RECRUITINGEARLY PHASE1NCT07126782The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT03222674Multi-CAR T Cell Therapy for Acute Myeloid LeukemiaShenzhen Geno-Immune Medical Institute
- RECRUITINGNCT06513273Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)Gruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT07023588Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseYehui Tan
See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) →